VivoSeq
Infectious Disease

Bronchiolitis Obliterans

30

Pipeline Programs↗

7

Active Trials↗

19

Companies Involved↗

Bronchiolitis Obliterans is an emerging landscape with 30 programs across 19 companies. The most active players are Regend Therapeutics, AstraZeneca, APT Pharmaceuticals, Inc.. 9 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

6/100

Mech. Concentration

20/100

Completion Rate

77/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

R

Regend Therapeutics

1 program

Phase 1AstraZeneca logo

AstraZeneca

2 programs

Phase 2A

APT Pharmaceuticals, Inc.

1 program

Phase 2H

Horizon Therapeutics Ireland DAC

1 program

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2GSK logo

GSK

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

97%

Small molecule

32 of 33 classified programs — the dominant modality here.

3%ALL OTHERSMonoclonal antibody13%

Small molecule leads; the ring shows all 33 classified programs, each share of the total. Modality classified for 100% of 34 pipeline programs.

Analysis

Trial Status

33

clinical trials

Completed17 · 52%
Recruiting5 · 15%
Terminated5 · 15%
Unknown status4 · 12%
Active, not recruiting2 · 6%

Clinical Trials

Trial Activity

33 trials

LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.
Recruiting·SSteven Hays, MD·Phase 2·NCT06018766·30 enrolled
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
Recruiting·—·Phase 2·NCT05922761·45 enrolled
Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant
Recruiting·RRenovion, Inc.·Phase 3·NCT05654922·100 enrolled
Treatment of Pediatric Bronchiolitis Obliterans by Airway Basal Stem Cells
Recruiting·RRegend Therapeutics·Phase 1·NCT07239895·12 enrolled
Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation
Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 2·NCT03805477·20 enrolled
Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)
Active, not recruiting·MMassachusetts General Hospital·Phase 2·NCT03674047·50 enrolled
Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
Active, not recruiting·National Cancer Institute (NCI)·Phase 1/2·NCT02669251·14 enrolled
Vitamin D in Bronchiolitis Obliterans Syndrome
Completed·UUniversitaire Ziekenhuizen KU Leuven·Phase 4·NCT01212406·100 enrolled
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)
Completed·—·Phase 3·NCT03656926·169 enrolled
Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans Following Stem Cell Transplantation
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT01560689·32 enrolled
Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Syndrome
Completed·National Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT01287078·25 enrolled
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)
Completed·—·Phase 3·NCT03657342·62 enrolled
Nintedanib in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome Grade 0p-1-2
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT03283007·58 enrolled
Early Detection and Management of Bronchiolitis Obliterans Syndrome Following Pediatric Hematopoietic Stem Cell Transplantation
Completed·—·N/A·NCT03072849·23 enrolled
Montelukast in Bronchiolitis Obliterans Syndrome
Completed·UUniversitaire Ziekenhuizen KU Leuven·Phase 4·NCT01211509·30 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)